The present invention provides a conjugate of formula (I) and its use in methods of treatment, and also methods for delivering an active agent into a cell. The methods may be used to deliver an active agent into a nematode, flatworm, parasite or bacterium. The conjugate of formula (I) is: (formula (I)), wherein -D- is C.sub.1-4 alkylene or C.sub.2-4 alkenylene, preferably C.sub.2-4 alkenylene, where the alkylene or alkenylene is optionally substituted with alkyl or halo; A- is an active agent for delivery; and —R.sup.A, —R.sup.B, —R.sup.T1, —R.sup.T2, —R.sup.1, —R.sup.2, —R.sup.3, —X— and -L- are as defined herein.

##STR00001##

The present invention provides a conjugate of formula (I) and its use in methods of treatment, and also methods for delivering an active agent into a cell. The methods may be used to deliver an active agent into a nematode, flatworm, parasite or bacterium. The conjugate of formula (I) is: (formula (I)), wherein -D- is C.sub.1-4 alkylene or C.sub.2-4 alkenylene, preferably C.sub.2-4 alkenylene, where the alkylene or alkenylene is optionally substituted with alkyl or halo; A- is an active agent for delivery; and —R.sup.A, —R.sup.B, —R.sup.T1, —R.sup.T2, —R.sup.1, —R.sup.2, —R.sup.3, —X— and -L- are as defined herein.

##STR00001##

This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

Disclosed herein are compounds of Formula (I): ##STR00001##
and pharmaceutically acceptable salts thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.

Disclosed herein are compounds of Formula (I): ##STR00001##
and pharmaceutically acceptable salts thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.

The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

The present application relates to the use of heterocyclic compounds for controlling animal pests including arthropods, insects and nematodes, to novel heterocyclic compounds, to processes for their preparation and to intermediates for preparing the heterocyclic compounds.

An effective treatment method and composition for controlling a variety of diseases including disease in poultry are disclosed. The inventive concept set forth herein provides an improved long-lasting treatment having a positive latency effect for a broad variety of diseases that is easy to administer and cost effective. The disclosed method of treatment utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. By administering the compound early in broiler life, disease prevention and treatment via immune modulation result. The treatment has a lasting effect throughout the entire broiler production period. The composition itself is a natural product and thus has no adverse environmental impact unlike known antibiotic regimens. By providing effective treatment during the stage of life where feed consumption is lowest by volume, costs to the producer are advantageously limited.

Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.